Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMS CoTSE:4891 +3.13%31 14-Day RSI is 79.63 as of Sep. 21, 2026. GuruFocus rates TSE:4891 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, TMS Co ranks worse than 99.15% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-21), TMS Co's 14-Day RSI is 79.63.
The industry rank for TMS Co's 14-Day RSI or its related term are showing as below:
TSE:4891's 14-Day RSI is ranked worse than 99.15% of 1416
companies
in the Biotechnology industry
Industry Median: 45.415
vs TSE:4891: 79.63
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
TMS Co 14-Day RSI Related Terms
TSE:4891 vs VRTX, REGN, MRNA: 14-Day RSI Comparison
For the Biotechnology subindustry, TMS Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMS Co 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TMS Co's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where TMS Co's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co (TSE:4891) has a 14-Day RSI of 79.63 as of Sep. 21, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TMS Co and its competitors. According to the industry distribution chart, TMS Co ranks #1404 out of 1416 companies in the Biotechnology industry, placing it in the top 99.2%.
Is TMS Co's 14-Day RSI too high?
TMS Co's current 14-Day RSI is 79.63. The Biotechnology industry median 14-Day RSI is 45.42. TMS Co's value of 79.63 is 75.3% above this industry median. Based on the distribution chart, TMS Co ranks #1404 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TMS Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TMS Co ranks #1404 out of 1416 companies for 14-Day RSI. This places TMS Co in the lower half of its industry. The industry median 14-Day RSI is 45.42. TMS Co's value of 79.63 is 75.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.42, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMS Co's current 14-Day RSI of 79.63 is 75.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TMS Co and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMS Co's current 14-Day RSI is 79.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current 14-Day RSI of 79.63. The current 14-Day RSI is 79.63 and 75.3% above the Biotechnology industry median of 45.42. TMS Co's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For TMS Co (TSE:4891), the current 14-Day RSI is 79.63 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
31GF Score
Get the complete analysis for TSE:4891
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4891 has been successfully added to your 
